Ultragenyx settles DOJOLVI patent suit, grants Esjay generic entry from 2033

Reuters2026/08/11 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ultragenyx settled New Jersey patent litigation tied to Esjay’s ANDA for a generic version of DOJOLVI (triheptanoin) oral liquid.
Deal grants Esjay a non-exclusive, royalty-free license to launch a generic starting Jan. 1, 2033.
Launch shifts to July 1, 2033 if DOJOLVI receives pediatric exclusivity, subject to customary conditions.
Patent suits against other DOJOLVI ANDA filers remain pending in the same court.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-343525), on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ultragenyx settles DOJOLVI patent suit, grants Esjay generic entry from 2033

You may also like

Crypto prices